Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$2.34
+1.7%
$2.08
$1.09
▼
$2.84
$348.38M0.611.58 million shs1.95 million shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.04
-4.6%
$1.62
$0.80
▼
$2.95
$153.27M2.381.07 million shs472,000 shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$13.80
+1.6%
$11.04
$7.20
▼
$45.00
$339.34M-0.04143,424 shs171,083 shs
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$7.56
+0.7%
$8.60
$6.47
▼
$10.71
$53.37M-0.1331,517 shs20,098 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
-10.51%-6.12%+16.75%-2.54%+88.52%
InflaRx N.V. stock logo
IFRX
InflaRx
-1.80%-12.10%-29.22%-48.10%-13.49%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-2.23%-13.17%+40.00%-12.56%-21.14%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-1.57%-8.86%-12.06%-18.63%-33.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$2.34
+1.7%
$2.08
$1.09
▼
$2.84
$348.38M0.611.58 million shs1.95 million shs
InflaRx N.V. stock logo
IFRX
InflaRx
$1.04
-4.6%
$1.62
$0.80
▼
$2.95
$153.27M2.381.07 million shs472,000 shs
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$13.80
+1.6%
$11.04
$7.20
▼
$45.00
$339.34M-0.04143,424 shs171,083 shs
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$7.56
+0.7%
$8.60
$6.47
▼
$10.71
$53.37M-0.1331,517 shs20,098 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
-10.51%-6.12%+16.75%-2.54%+88.52%
InflaRx N.V. stock logo
IFRX
InflaRx
-1.80%-12.10%-29.22%-48.10%-13.49%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-2.23%-13.17%+40.00%-12.56%-21.14%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-1.57%-8.86%-12.06%-18.63%-33.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.43
Hold$5.10117.95% Upside
InflaRx N.V. stock logo
IFRX
InflaRx
2.67
Moderate Buy$7.43614.29% Upside
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
2.78
Moderate Buy$40.00189.86% Upside
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
2.00
Hold$16.00111.64% Upside

Current Analyst Ratings Breakdown

Latest XLO, ALEC, LYEL, and IFRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Alector, Inc. stock logo
ALEC
Alector
Initiated CoverageOverweight$7.00
11/13/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Lower Price TargetBuy$45.00 ➝ $39.00
11/11/2026
Alector, Inc. stock logo
ALEC
Alector
Reiterated RatingSell (D-)
11/6/2026
Alector, Inc. stock logo
ALEC
Alector
Initiated CoverageStrong-Buy
11/4/2026
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
UpgradeSell (E+) ➝ Sell (D-)
11/3/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Reiterated RatingBuy$44.00
10/23/2026
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
10/22/2026
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
UpgradeHold
10/21/2026
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
Initiated CoverageOutperform$16.00
10/15/2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
Reiterated RatingSell (D-)
10/14/2026
Alector, Inc. stock logo
ALEC
Alector
Boost Price TargetBuy$5.00 ➝ $8.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$21.05M16.55N/AN/A$0.78 per share3.00
InflaRx N.V. stock logo
IFRX
InflaRx
$30K5,108.83N/AN/A$1.13 per share0.92
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
$40K8,483.55N/AN/A$7.84 per share1.76
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$43.77M1.22N/AN/A$9.66 per share0.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$142.93M$0.356.69N/A0.1623.87%112.21%18.37%N/A
InflaRx N.V. stock logo
IFRX
InflaRx
-$51.63M-$0.39N/AN/AN/AN/A-32.04%-27.33%N/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$274.45M-$12.56N/AN/AN/A-1,701,066.75%-107.62%-80.01%N/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$35.04M-$0.40N/AN/AN/A-20.89%-60.54%-24.76%N/A

Latest XLO, ALEC, LYEL, and IFRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$0.9350-$0.30+$0.6350-$0.30$4.92 million$9.98 million
11/5/2026Q3 2026
Alector, Inc. stock logo
ALEC
Alector
-$0.2259$1.11+$1.3359$1.11$2.19 million$162.87 million
11/4/2026Q3 2026
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
-$2.0063-$1.86+$0.1463-$1.6890$0.00 million$0.00 million
11/3/2026Q3 2026
InflaRx N.V. stock logo
IFRX
InflaRx
-$0.0631-$0.02+$0.0431-$0.02$0.01 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
InflaRx N.V. stock logo
IFRX
InflaRx
N/AN/AN/AN/AN/A
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/AN/AN/AN/AN/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
N/A
4.10
4.10
InflaRx N.V. stock logo
IFRX
InflaRx
N/A
7.26
7.26
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
N/A
4.02
4.02
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/A
4.72
4.72

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
InflaRx N.V. stock logo
IFRX
InflaRx
42.39%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
66.05%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
54.29%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
8.30%
InflaRx N.V. stock logo
IFRX
InflaRx
16.30%
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
6.20%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
7.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
103148.88 million136.52 millionOptionable
InflaRx N.V. stock logo
IFRX
InflaRx
65147.37 million123.35 millionOptionable
Lyell Immunopharma, Inc. stock logo
LYEL
Lyell Immunopharma
16124.59 million23.06 millionOptionable
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
767.06 million6.54 millionNot Optionable

Recent News About These Companies

Xilio Names Yariv Houvras Chief Medical Officer
Xilio Therapeutics Appoints Yariv J. Houvras, M.D.
Xilio Therapeutics Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alector stock logo

Alector NASDAQ:ALEC

$2.34 +0.04 (+1.74%)
Closing price 04:00 PM Eastern
Extended Trading
$2.34 0.00 (-0.21%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

InflaRx stock logo

InflaRx NASDAQ:IFRX

$1.04 -0.05 (-4.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.04 0.00 (0.00%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Lyell Immunopharma stock logo

Lyell Immunopharma NASDAQ:LYEL

$13.80 +0.22 (+1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$13.84 +0.04 (+0.29%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Xilio Therapeutics stock logo

Xilio Therapeutics NASDAQ:XLO

$7.56 +0.05 (+0.67%)
Closing price 04:00 PM Eastern
Extended Trading
$7.52 -0.04 (-0.53%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.